{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:43:18Z","timestamp":1794012198383,"version":"4.8.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) has recently emerged as a key indicator of neurodegeneration. In this study, our hypothesis is that the levels of blood-derived NfL and its accumulation during the Parkinson\u2019s disease (PD) progression could serve as a potential biomarker for predicting subsequent cognitive decline. To investigate this, we conducted a study utilizing a large single-center cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 193 participants, consisting of 106 cognitively normal PD (PD-CN) patients and 87 normal controls (NC) individuals. Serum NfL concentrations were measured. PD patients were followed up for clinical assessment at an average of 2 \u00b1 0.6 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The serum NfL levels were significantly higher in PD-CN patients compared to NC. PD-CN patients and NC at follow-up time exhibited higher serum NfL levels compared to those at baseline. PD patients with high serum NfL levels were found to have a higher likelihood of transitioning from normal cognition to mild cognitive impairment (MCI) or dementia (Hazard ratio (HR) 1.107, 95% confidence intervals (CI) 1.010\u20131.213,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.030). The area under the curve (AUC) for PD-CN conversion to MCI or dementia at follow-up time was determined to be 0.684 (95% CI 0.569\u20130.799).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, our study found that PD patients have significantly higher levels of serum NfL compared to individuals without PD. Furthermore, serum NfL levels increase as PD progresses and can predict cognitive impairment within a 2-year timeframe. Serum NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD. However, further studies and functional experiments are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2024.1465016","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:29:22Z","timestamp":1733362162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson\u2019s disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Lihua","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament light chain as a biomarker for cognitive decline in parkinson disease.","volume":"36","author":"Aamodt","year":"2021","journal-title":"Mov. Disord."},{"key":"B2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease.","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.neuron.2016.07.007","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases.","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: A meta-analysis.","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov. Disord."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00384-x","article-title":"Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease.","volume":"8","author":"Batzu","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis.","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1212\/WNL.0b013e31829c5c86","article-title":"Evolution of mild cognitive impairment in Parkinson disease.","volume":"81","author":"Broeders","year":"2013","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mds.28909","article-title":"Age-adjusted serum neurofilament predicts cognitive decline in Parkinson\u2019s disease (MARK-PD).","volume":"37","author":"Buhmann","year":"2022","journal-title":"Mov. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JPD-191766","article-title":"Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson\u2019s disease.","volume":"10","author":"Chen","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","article-title":"The MoCA: Well-suited screen for cognitive impairment in Parkinson disease.","volume":"75","author":"Dalrymple-Alford","year":"2010","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease.","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease.","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1567205020666230601123123","article-title":"Blood neurofilament light chain in different types of dementia.","volume":"20","author":"Gu","year":"2023","journal-title":"Curr. Alzheimer Res."},{"key":"B15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3181e7948a","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.","volume":"75","author":"Kasten","year":"2010","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders.","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","article-title":"Cognitive decline and quality of life in incident Parkinson\u2019s disease: The role of attention.","volume":"27","author":"Lawson","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B19","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: A biomarker for disease severity and progression in Parkinson disease.","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease.","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3233\/JPD-212535","article-title":"Serum neurofilament dynamics predicts cognitive progression in de novo Parkinson\u2019s disease.","volume":"11","author":"Ma","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"B22","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms.","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/mds.23388","article-title":"Gender differences in Parkinson\u2019s disease: Clinical characteristics and cognition.","volume":"25","author":"Miller","year":"2010","journal-title":"Mov. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression.","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","article-title":"Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson\u2019s disease (MARK-PD).","volume":"90","author":"Niemann","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype.","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00128","article-title":"Increased CSF NFL in non-demented Parkinson\u2019s disease subjects reflects early white matter damage.","volume":"12","author":"Papu\u0107","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3233\/JAD-150610","article-title":"Vascular risk factors and cognition in Parkinson\u2019s disease.","volume":"51","author":"Pilotto","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187939","article-title":"White matter alterations in Parkinson\u2019s disease with normal cognition precede grey matter atrophy.","volume":"13","author":"Rektor","year":"2018","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.parkreldis.2020.04.009","article-title":"Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson\u2019s disease.","volume":"74","author":"Sampedro","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106237","article-title":"Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson\u2019s disease.","volume":"185","author":"Urso","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3233\/JAD-190615","article-title":"Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: A systematic review and meta-analysis.","volume":"72","author":"Wang","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B36","article-title":"Management of psychiatric and cognitive complications in Parkinson\u2019s disease.","volume":"379","author":"Weintraub","year":"2022","journal-title":"Bmj"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/mds.28026","article-title":"Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson\u2019s disease.","volume":"35","author":"Wilke","year":"2020","journal-title":"Mov. Disord."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00572-3","article-title":"Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson\u2019s disease.","volume":"9","author":"Yang","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae130","article-title":"Neuroimaging and plasma evidence of early white matter loss in Parkinson\u2019s disease with poor outcomes.","volume":"6","author":"Zarkali","year":"2024","journal-title":"Brain Commun."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1465016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:29:31Z","timestamp":1733362171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1465016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"alternative-id":["10.3389\/fnagi.2024.1465016"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2024.1465016","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"article-number":"1465016"}}